Inhibitory effect of arazyme on the development of atopic dermatitis-like lesions in BALB/c and Nc/Nga mice

Kim,In  Sik; Lee,Na  Rae; Baek,Seung  Yeop; Kim,Eun  Jeong; Kim,Jung  Seok; Jeong,Tae‑Sook; Shin,Dong‑Ha; Park,Ho‑Yong; Lee,Ji‑Sook

doi:10.3892/mmr.2015.3225

Inhibitory effect of arazyme on the development of atopic dermatitis-like lesions in BALB/c and Nc/Nga mice

Authors:
- In Sik Kim
- Na Rae Lee
- Seung Yeop Baek
- Eun Jeong Kim
- Jung Seok Kim
- Tae‑Sook Jeong
- Dong‑Ha Shin
- Ho‑Yong Park
- Ji‑Sook Lee
View Affiliations

Affiliations: Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301‑746, Republic of Korea, Industrial Bio‑material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305‑806, Republic of Korea, Insect Biotech Co., Ltd., Daejeon 305‑811, Republic of Korea, Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan 570‑750, Republic of Korea
Published online on: January 19, 2015 https://doi.org/10.3892/mmr.2015.3225
Pages: 3995-4001

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arazyme is a metalloprotease released by Aranicola proteolyticus that was shown to inhibit cytokine release in HaCaT and endothelial cells. However, the regulatory effects of arazyme in atopic dermatitis remain to be fully understood. In the present study, the anti‑inflammatory effects of arazyme in BALB/c and Nc/Nga mice induced with 2,4‑dinitrochlrobenzene (DNCB) were investigated. BALB/c mice were sensitized with DNCB and were subsequently administered arazyme for 4 weeks either orally, dorsally or orally/dorsally. Arazyme administration significantly reduced epidermal thickening and infiltration of inflammatory cells into the dermis compared with the DNCB group. However, serum immunoglobulin E (IgE) levels were not altered by arazyme treatment. Additionally, the level of secretion of interleukins (IL)‑4, ‑5 and ‑13 in the splenocytes of BALB/c mice was elevated following stimulation with concanavalin A, while the increase of IL‑4 and IL‑13 was inhibited by arazyme. Administration of arazyme (25 mg/kg in phosphate‑buffered saline) to Nc/Nga mice that had been sensitized with DNCB for 6 weeks reduced the skin severity score compared with that in the DNCB group and inhibited the histological manifestations of atopic dermatitis‑like skin lesions. In addition, the serum IgE levels were reduced in the arazyme‑treated NC/Nga mice relative to the DNCB group. Collectively, these results indicated that arazyme attenuates the development of atopic dermatitis‑like lesions via lowering the levels of IgE and inflammatory cytokines. The results of the present study will aid in the development of effective therapeutic strategies for the treatment of allergic diseases, including atopic dermatitis.

View Figures

View References

1	Bieber T: Atopic dermatitis. N Engl J Med. 358:1483–1494. 2008. View Article : Google Scholar : PubMed/NCBI
2	Barnes KC: An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 125:16–29. 2010. View Article : Google Scholar : PubMed/NCBI
3	Habu Y, Seki S, Takayama E, Ohkawa T, Koike Y, Ami K, Majima T and Hiraide H: The mechanism of a defective IFN-gamma response to bacterial toxins in an atopic dermatitis model, NC/Nga mice, and the therapeutic effect of IFN-gamma, IL-12, or IL-18 on dermatitis. J Immunol. 166:5439–5447. 2001. View Article : Google Scholar : PubMed/NCBI
4	Jin H, He R, Oyoshi M and Geha RS: Animal models of atopic dermatitis. J Invest Dermatol. 129:31–40. 2009. View Article : Google Scholar
5	Shiohara T, Hayakawa J and Mizukawa Y: Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci. 36:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
6	Berke R, Singh A and Guralnick M: Atopic dermatitis: an overview. Am Fam Physician. 86:35–42. 2012.PubMed/NCBI
7	Bersanetti PA, Park HY, Bae KS, Son KH, Shin DH, Hirata IY, Juliano MA, Carmona AK and Juliano L: Characterization of arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture medium. Enzyme Microb Technol. 37:574–581. 2005. View Article : Google Scholar
8	Kwak J, Lee K, Shin DH, Maeng JS, Park DS, Oh HW, Son KH, Bae KS and Park HY: Biochemical and genetic characterization of arazyme, an extracellular metalloprotease produced from Serratia proteamaculans HY-3. J Microbiol Biotechnol. 17:761–768. 2007.PubMed/NCBI
9	Kim IS, Kim MJ, Shin DH, Son KH, Park HY and Lee JS: Arazyme inhibits cytokine expression and upregulates skin barrier protein expression. Mol Med Rep. 8:551–556. 2013.PubMed/NCBI
10	Kim IS, Yang EJ, Shin DH, Son KH, Park HY and Lee JS: Effect of arazyme on the lipopolysaccharide-induced inflammatory response in human endothelial cells. Mol Med Rep. 10:1025–1029. 2014.PubMed/NCBI
11	Lee JS, Kim IS, Ryu JS, Kim JH, Kim JS, Kim DH and Yun CY: The inhibitory effect of Duchesnea chrysantha extract on the development of atopic dermatitis-like lesions by regulating IgE and cytokine production in Nc/Nga mice. Phytother Res. 26:284–290. 2012. View Article : Google Scholar
12	Kim IS, Kim DH, Yun CY and Lee JS: A (S)-(+)-decursin derivative, (S)-(+)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]-chromen-3-yl-ester, attenuates the development of atopic dermatitis-like lesions in NC/Nga mice. Mol Biol Rep. 40:2541–2548. 2013. View Article : Google Scholar : PubMed/NCBI
13	Witter RF and Grubbs LM: An evaluation of the Reitman-Frankel method for the determination of serum glutamic oxalacetic transaminase. Clin Chim Acta. 13:524–527. 1966. View Article : Google Scholar : PubMed/NCBI
14	Park JK, Jeong DH, Park HY, Son KH, Shin DH, Do SH, Yang HJ, Yuan DW, Hong IH, Goo MJ, Lee HR, Ki MR, Ishigami A and Jeong KS: Hepatoprotective effect of Arazyme on CCl4-induced acute hepatic injury in SMP30 knock-out mice. Toxicology. 246:132–142. 2008. View Article : Google Scholar : PubMed/NCBI
15	Tanaka A, Amagai Y, Oida K and Matsuda H: Recent findings in mouse models for human atopic dermatitis. Exp Anim. 61:77–84. 2012. View Article : Google Scholar : PubMed/NCBI
16	Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol. 12:227–257. 1994. View Article : Google Scholar : PubMed/NCBI
17	Suto H, Matsuda H, Mitsuishi K, Hira K, Uchida T, Unno T, Ogawa H and Ra C: NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol. 120(Suppl 1): 70–75. 1999. View Article : Google Scholar : PubMed/NCBI
18	Yang EJ, Lee JS, Yun CY, Kim JH, Kim JS, Kim DH and Kim IS: Inhibitory effects of Duchesnea chrysantha extract on ovalbumin-induced lung inflammation in a mouse model of asthma. J Ethnopharmacol. 118:102–107. 2008. View Article : Google Scholar : PubMed/NCBI
19	Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T and Atamas SP: Regulation of inflammation by interleukin-4: a review of “alternatives”. J Leukoc Biol. 92:753–764. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yamanaka K and Mizutani H: The role of cytokines/chemokines in the pathogenesis of atopic dermatitis. Curr Probl Dermatol. 41:80–92. 2011. View Article : Google Scholar : PubMed/NCBI